Compare Prudential Financial Inc (PRU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Prudential Financial Inc trades at $117.62 (market cap $41.19B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.3× Prudential Financial Inc's market cap, and Prudential Financial Inc pays a 4.69% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PRU | VRTX | |
|---|---|---|
Market Cap | $41.19B | $134.06B |
Sector | Financials | Health |
52-Week High | $125.13 | $557.96 |
52-Week Low | $92.00 | $376.62 |
Enterprise Value | $69.96B | $128.18B |
Dividend Yield | 4.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRU trades at $119.38, down 2.16% today, with a neutral technical outlook and mixed earnings history. The stock shows strong profitability with a 6.04% net margin and 12.46% ROE, while valuation metrics like a P/E of 10.82 and P/S of 0.64 appear attractive. Recent news highlights PGIM's ETF launches and conference participation, signaling strategic focus.
The outlook is cautious; analyst consensus is a Hold with a $113.20 target below the current price. Risks include volatile cash flows and high leverage, but steady dividends and earnings beats offer support. Upside depends on execution of cost reductions and capital-light growth amid economic uncertainty.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
